Diamedica Therapeutics Inc (DMAC)
NASDAQ:DMAC
US Market
Holding DMAC?
Track your performance easily

Diamedica Therapeutics (DMAC) Income Statement

477 Followers

Diamedica Therapeutics Income Statement

Last quarter (Q2 2024), Diamedica Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, Diamedica Therapeutics's net income was $-5.12M. See Diamedica Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
------
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 10.90M$ 21.27M$ 14.00M$ 13.65M$ 12.70M$ -11.59M
Operating Income
$ -22.38M$ -21.27M$ -14.00M$ -13.65M$ -12.70M$ -11.59M
Net Non Operating Interest Income Expense
-----$ 856.00K
Other Income Expense
$ 279.00K$ 1.93M$ 353.00K$ -82.00K$ -434.00K$ -119.00K
Pretax Income
$ -19.86M$ -19.34M$ -13.65M$ -13.56M$ -12.27M$ -10.62M
Tax Provision
$ 43.00K$ 43.00K$ 28.00K$ 28.00K$ 27.00K$ 31.00K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -19.90M$ -19.38M$ -13.68M$ -13.59M$ -12.29M$ -10.65M
Basic EPS
$ -0.51$ -0.60$ -0.52$ -0.65$ -0.78-
Diluted EPS
$ -0.51$ -0.60$ -0.52$ -0.65$ -0.78$ -0.89
Basic Average Shares
$ 152.53M$ 32.57M$ 26.44M$ 20.77M$ 15.68M$ 11.99M
Diluted Average Shares
$ 152.53M$ 32.57M$ 26.44M$ 20.77M$ 15.68M$ 11.97M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 10.90M$ 21.27M$ 14.00M$ 13.65M$ 12.70M$ -11.59M
Net Income From Continuing And Discontinued Operation
$ -19.90M$ -19.38M$ -13.68M$ -13.59M$ -12.29M$ -10.65M
Normalized Income
$ -17.75M$ -15.29M-$ -10.73M--
Interest Expense
------
EBIT
$ -9.78M$ -21.27M$ -14.00M$ -13.65M$ -12.49M$ -10.62M
EBITDA
$ -9.74M$ -21.24M$ -13.98M$ -13.62M$ -12.47M$ -10.67M
Currency in USD

Diamedica Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis